BioAge is a platform-driven, clinical-stage biotechnology company that is mapping human aging to develop a pipeline of therapies that treat disease and extend healthy lifespan. Our proprietary human-first platform encompasses >65M molecular measurements spanning 45+ years of human aging, and unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. We currently have three clinical programs in our growing portfolio–two first in class and two first in indication–for immune aging and muscle aging. Ultimately, our mission is to develop therapies that change the nature of aging and provide patients with years more healthy time. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others.